Efficacy and safety of application of topical β-adrenoblocator for treatment of juvenile hemangioma

Juvenile hemangiomas (JH) are the most common tumors of childhood, which, according to various researchers, occur in 3-12% of newborns. A new approach to the pharmacotherapy of JH is based on the effectiveness of the β-adrenergic blocker (β-AB timolol), and topical therapy of JH with β-AB appears the most relevant method of treatment of focal surface hemangiomas. Objective: to evaluate the properties of timolol in vitro, its clinical efficacy and safety in topical antiangiogenic therapy in children with superficial focal JH. Methods. Cytotoxicity, the effect of timolol on metabolism and active migration of cells in vitro (LDG test, WST test, cell migration and restoration of confluency of monolayer of cell culture) were evaluaeted. The clinical efficacy and safety of the use of β-AB in the treatment of children with superficial JH (n=56) was assessed. Results. The experimental studies in vitro indicate the absence of a negative effect of timolol on the viability, migration and mobility of endothelial cells, fibroblasts and keratinocytes. The results of the studies indicate safety and high clinical efficacy: recovery was observed in 87.5%, a significant improvement - in 7.1%, and effect of treatment was absent in 5.3%. Side effects in the treatment of children (cases of hypoglycemia and heart conduction disorders) were not detected. Conclusion. The results of the study make it possible to recommend the widespread introduction of active anti-angiogenic therapy with non-selective ß-AB timolol for surface JHs.

juvenile hemangiomas, treatment, β-adrenoblocker, timolol